Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Nutrients ; 15(7)2023 Mar 28.
Article in English | MEDLINE | ID: mdl-37049474

ABSTRACT

Caffeine is an adenosine A2A receptor (ADORA2A) antagonist with ergogenic and anti-inflammatory effects. Previous studies have reported that the ADORA2A gene regulates glutamate metabolism and immune responses, with the ADORA2A rs5751876 TT genotype (with high sensitivity to caffeine) showing larger ergogenic effect following caffeine ingestion. We therefore hypothesized that the TT genotype would be associated with greater anti-inflammatory effects of caffeine in response to exercise, and with higher coffee intake in physically active individuals. The aim of the present study was twofold: (1) to investigate the association of the ADORA2A variant with the anti-inflammatory effects of caffeine in response to intense resistance exercise (RE), and (2) to analyze the association of the rs5751876 with coffee intake in physically active individuals (n = 134). Fifteen resistance-trained athletes participated in a randomized, double-blind, placebo-controlled cross-over study, where they consumed 6 mg/kg of caffeine or placebo one hour prior to performing an RE protocol. Blood samples were taken immediately from the arterial vein before, immediately after, and 15 min after RE for the analysis of inflammatory markers myeloperoxidase (MPO) and acetylcholinesterase (AChE). We found that the ADORA2A TT genotype carriers experienced lower exercise-induced inflammatory responses (p < 0.05 for AchE) when compared to the C allele carriers (i.e., CC/CT) one hour following the ingestion of caffeine. Furthermore, the ADORA2A TT genotype was positively associated with coffee intake (p = 0.0143; irrespective of CYP1A2 rs762551 polymorphism). In conclusion, we found that the ADORA2A gene polymorphism is associated with anti-inflammatory effects of caffeine in response to resistance exercise, as well as with habitual coffee intake in physically active individuals.


Subject(s)
Caffeine , Resistance Training , Humans , Receptor, Adenosine A2A/genetics , Coffee , Cross-Over Studies , Acetylcholinesterase , Heterozygote , Anti-Inflammatory Agents/pharmacology , Cytochrome P-450 CYP1A2/genetics , Genotype
2.
Curr Aging Sci ; 15(1): 65-76, 2022 02 03.
Article in English | MEDLINE | ID: mdl-34042043

ABSTRACT

BACKGROUND: Parkinsonism is a neurodegenerative disorder that affects elderly people worldwide. METHODS: Curcumin, adenosine A2AR antagonist (ZM241385) and Sinemet® (L-dopa) were evaluated against Parkinson's disease (PD) induced by rotenone in rats, and the findings were compared to our previous study on mice model. RESULTS: Rats injected with rotenone showed severe alterations in adenosine A2A receptor gene expression, oxidative stress markers, inflammatory mediator, energetic indices, apoptotic marker and DNA fragmentation levels as compared to the control group. Treatments with curcumin, ZM241385, and Sinemet® restored all the selected parameters. The brain histopathological features of cerebellum regions confirmed our results. By comparing our results with the previous results on mice, we noticed that mice respond to rotenone toxicity and treatments more than rats with regards to behavioral observation, A2AR gene expression, neurotransmitter levels, inflammatory mediator and apoptotic markers, while rats showed higher response to treatments regarding oxidative stress and energetic indices. CONCLUSION: Curcumin succeeded in attenuating the severe effects of Parkinson's disease in the rat model and can be considered as a potential dietary supplement. Adenosine A2AR antagonist has almost the same pattern of improvement as Sinemet® and may be considered as a promising therapy against PD. To compare the role of animal species in response to PD symptoms and treatments, our previous report on mice explored the response of mice to rotenone toxicity in comparison with rats, where rats have shown a higher response to treatments. Therefore, no animal model can perfectly recapitulate all the pathologies of PD.


Subject(s)
Curcumin , Neuroprotective Agents , Parkinson Disease , Parkinsonian Disorders , Adenosine , Aged , Animals , Curcumin/pharmacology , Disease Models, Animal , Dopamine Agonists , Humans , Inflammation Mediators , Mice , Neuroprotective Agents/pharmacology , Parkinson Disease/drug therapy , Parkinson Disease/etiology , Parkinson Disease/metabolism , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/drug therapy , Rats , Receptor, Adenosine A2A/genetics , Receptor, Adenosine A2A/metabolism , Rotenone/pharmacology
3.
Biochem Biophys Res Commun ; 586: 20-26, 2022 01 01.
Article in English | MEDLINE | ID: mdl-34823218

ABSTRACT

Curcumin is a natural polyphenol derived from the turmeric plant (Curcuma longa) which exhibits numerous beneficial effects on different cell types. Inhibition of platelet activation by curcumin is well known, however molecular mechanisms of its action on platelets are not fully defined. In this study, we used laser diffraction method for analysis of platelet aggregation and Western blot for analysis of intracellular signaling mechanisms of curcumin effects on platelets. We identified two new molecular mechanisms involved in the inhibitory effects of curcumin on platelet activation. Firstly, curcumin by activation of adenosine A2A receptor stimulated protein kinase A activation and phosphorylation of Vasodilator-stimulated phosphoprotein. Secondly, we demonstrated that curcumin even at low doses, which did not inhibit platelet aggregation, potentiated inhibitory effect of ADP receptor P2Y12 antagonist cangrelor which partly could be explained by activation of adenosine A2A receptor.


Subject(s)
Adenosine Monophosphate/analogs & derivatives , Blood Platelets/drug effects , Cell Adhesion Molecules/genetics , Curcumin/pharmacology , Cyclic AMP-Dependent Protein Kinases/genetics , Microfilament Proteins/genetics , Phosphoproteins/genetics , Platelet Activation/drug effects , Receptor, Adenosine A2A/genetics , Adenosine Diphosphate/pharmacology , Adenosine Monophosphate/pharmacology , Blood Platelets/cytology , Blood Platelets/metabolism , Cell Adhesion Molecules/metabolism , Curcuma/chemistry , Curcumin/isolation & purification , Cyclic AMP-Dependent Protein Kinases/metabolism , Drug Synergism , Gene Expression Regulation , Humans , Microfilament Proteins/metabolism , Phosphoproteins/metabolism , Phosphorylation , Plant Extracts/chemistry , Platelet Aggregation Inhibitors/pharmacology , Primary Cell Culture , Purinergic P2Y Receptor Antagonists/pharmacology , Receptor, Adenosine A2A/metabolism , Receptors, Purinergic P2Y12/genetics , Receptors, Purinergic P2Y12/metabolism , Signal Transduction
4.
Article in English | MEDLINE | ID: mdl-33373678

ABSTRACT

Many people consume coffee to attenuate increased sleepiness and impaired vigilance and attention due to insufficient sleep. We investigated in genetically caffeine sensitive men and women whether 'real world' coffee consumption during a simulated busy work week counteracts disabling consequences of chronically restricted sleep. We subjected homozygous C-allele carriers of ADORA2A (gene encoding adenosine A2A receptors) to five nights of only 5 h time-in-bed. We administered regular coffee (n = 12; 200 mg caffeine at breakfast and 100 mg caffeine after lunch) and decaffeinated coffee (n = 14) in double-blind fashion on all days following sleep restriction. At regular intervals four times each day, participants rated their sleepiness and performed the psychomotor vigilance test, the visual search task, and the visuo-spatial and letter n-back tasks. At bedtime, we quantified caffeine and the major caffeine metabolites paraxanthine, theobromine and theophylline in saliva. The two groups did not differ in age, body-mass-index, sex-ratio, chronotype and mood states. Subjective sleepiness increased in both groups across consecutive sleep restriction days and did not differ. By contrast, regular coffee counteracted the impact of repeated sleep loss on sustained and selective attention, as well as executive control when compared to decaffeinated coffee. The coffee also induced initial or transient benefits on different aspects of baseline performance during insufficient sleep. All differences between the groups disappeared after the recovery night and the cessation of coffee administration. The data suggest that 'real world' coffee consumption can efficiently attenuate sleep restriction-induced impairments in vigilance and attention in genetically caffeine sensitive individuals. German Clinical Trial Registry: # DRSK00014379.


Subject(s)
Attention/drug effects , Caffeine/administration & dosage , Coffee , Purinergic P1 Receptor Antagonists/administration & dosage , Receptor, Adenosine A2A/genetics , Sleep Deprivation/psychology , Adult , Alleles , Double-Blind Method , Female , Humans , Male , Neuropsychological Tests , Psychomotor Performance/drug effects , Sleep Deprivation/genetics , Wakefulness/drug effects
5.
Pharmacogenomics ; 21(11): 735-749, 2020 07.
Article in English | MEDLINE | ID: mdl-32615857

ABSTRACT

Aim: We studied the influence of coffee consumption on the therapeutic effect of methotrexate (MTX) in patients with rheumatoid arthritis (RA) sorted according to ADORA2A genotypes. Patients & methods: 82 RA patients were dichotomized according to caffeine intake with a threshold of 700 mg/week. Disease activity score 28 (DAS28) was applied (>3.2: high; <3.2: low or remission). Patients were genotyped using quantitative PCR allelic discrimination. Results: We found significantly higher risk of RA in patients with higher caffeine intake and the CT genotype of ADOARA2A rs2298383, rs3761422 and rs2267076 SNPs. The CC genotype of ADORA2A rs2236624 SNP in patients with lower caffeine intake treated with MTX is significantly protective. Conclusion:ADORA2A genotypes and coffee intake influence risk of RA and efficacy of it MTX treatment.


Subject(s)
Adenosine/genetics , Adenosine/metabolism , Arthritis, Rheumatoid/genetics , Arthritis, Rheumatoid/metabolism , Coffee/metabolism , Receptor, Adenosine A2A/genetics , Adult , Antirheumatic Agents/metabolism , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Coffee/adverse effects , Cross-Sectional Studies , Female , Humans , Male , Methotrexate/metabolism , Methotrexate/therapeutic use , Middle Aged , Polymorphism, Single Nucleotide/genetics , Signal Transduction/drug effects , Signal Transduction/physiology
6.
Biochem Biophys Res Commun ; 527(3): 662-667, 2020 06 30.
Article in English | MEDLINE | ID: mdl-32423816

ABSTRACT

Idiopathic Pulmonary fibrosis(PF)is a chronic progressive disease, which is a lack of effective treatment,and the pathogenesis of IPF is not fully elucidated. Asiaticoside(AS) is isolated from Centella asiatica and has the effect of promoting scar healing and reducing scar formation. However,its possible role in idiopathic pulmonary fibrosis remains unclear. Adenosine A2A receptor (A2AR) is reported a protective factor in pulmonary fibrosis, and the bone morphogenetic protein 7 (BMP7) signaling pathway plays a crucial role in fibrosis in multiple organs. But the impact of A2AR on the BMP7 pathway has not yet been reported. Therefore, we hypothesized AS may promote the expression of A2AR, and then influence the BMP7/Smad1/5 pathway to alleviate pulmonary fibrosis. A2AR-/- mice and wild-type (WT) mice were administered bleomycin (BLM) by intratracheal injection. AS (50 mg/kg/d) was given daily for 28 days. AS reduced collagen deposition in lung tissue, interstitial lung inflammation. Furthermore, AS promoted A2AR expression and BMP7 pathway. Collectively, AS may attenuate BLM-induced pulmonary fibrosis by upregulating the BMP7 signaling pathway through A2AR.


Subject(s)
Bone Morphogenetic Protein 7/metabolism , Pulmonary Fibrosis/drug therapy , Receptor, Adenosine A2A/genetics , Signal Transduction/drug effects , Smad Proteins/metabolism , Triterpenes/therapeutic use , Animals , Bleomycin , Centella/chemistry , Gene Deletion , Male , Mice , Mice, Inbred BALB C , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/genetics , Pulmonary Fibrosis/metabolism , Triterpenes/chemistry
7.
Nutrients ; 12(3)2020 Mar 11.
Article in English | MEDLINE | ID: mdl-32168870

ABSTRACT

Caffeine's ergogenic effects on exercise performance are generally explained by its ability to bind to adenosine receptors. ADORA2A is the gene that encodes A2A subtypes of adenosine receptors. It has been suggested that ADORA2A gene polymorphisms may be responsible for the inter-individual variations in the effects of caffeine on exercise performance. In the only study that explored the influence of variation in ADORA2A-in this case, a common polymorphism (rs5751876)-on the ergogenic effects of caffeine on exercise performance, C allele carriers were identified as "non-responders" to caffeine. To explore if C allele carriers are true "non-responders" to the ergogenic effects of caffeine, in this randomized, double-blind study, we examined the acute effects of caffeine ingestion among a sample consisting exclusively of ADORA2A C allele carriers. Twenty resistance-trained men identified as ADORA2A C allele carriers (CC/CT genotype) were tested on two occasions, following the ingestion of caffeine (3 mg/kg) and a placebo. Exercise performance was evaluated with movement velocity, power output, and muscle endurance during the bench press exercise, countermovement jump height, and power output during a Wingate test. Out of the 25 analyzed variables, caffeine was ergogenic in 21 (effect size range: 0.14 to 0.96). In conclusion, ADORA2A (rs5751876) C allele carriers exhibited ergogenic responses to caffeine ingestion, with the magnitude of improvements similar to what was previously reported in the literature among samples that were not genotype-specific. Therefore, individuals with the CT/CC genotype may still consider supplementing with caffeine for acute improvements in performance.


Subject(s)
Alleles , Caffeine/administration & dosage , Dietary Supplements , Heterozygote , Performance-Enhancing Substances/administration & dosage , Pharmacogenomic Variants , Receptor, Adenosine A2A/genetics , Adult , Body Mass Index , Cross-Over Studies , Exercise , Female , Humans , Male , Physical Endurance , Young Adult
8.
Ann Hematol ; 98(8): 1845-1854, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31154474

ABSTRACT

Primary immune thrombocytopenia is an autoimmune disease, characterized with decreased platelet and increased risk of bleeding. Recent studies have shown the reduction and dysfunction of regulatory T (Treg) cells in ITP patients. CD39 is highly expressed on the surface of Treg cells. It degrades ATP to AMP and CD73 dephosphorylates AMP into adenosine. Then adenosine binds with adenosine receptor and suppresses immune response by activating Treg cells and inhibiting the release of inflammatory cytokines from effector T (Teff) cells. Adenosine receptor has several subtypes and adenosine A2A receptor (A2AR) plays a crucial role especially within lymphocytes. The CD39+ Treg cells and the expression of A2AR showed abnormality in some autoimmune disease. But knowledge of CD39+ Treg cells and A2AR which are crucial in the adenosine immunosuppressive pathway is still limited in ITP. Thirty-one adult patients with newly diagnosed ITP were enrolled in this study. CD39 and A2AR expression was measured by flow cytometry and RT-PCR. The function of CD39 was reflected by the change of ATP concentration detected by CellTiter-Glo Luminescent Cell Viability Assay. CD39 expression within CD4+CD25+ Treg cells in ITP patients was decreased compared to normal controls. After high-dose dexamethasone therapy, response (R) group showed increased CD39 expression within Treg cells while non-response (NR) group did not show any difference in contrast to those before treatment. The expression of A2AR in CD4+CD25- Teff and CD4+CD25+ Treg cells was both lower in ITP patients than that of normal controls. After therapy, CD4+CD25- Teff cells had higher A2AR expression while CD4+CD25+ Treg cells did not show any difference in comparison to that before treatment. The enzymatic activity of CD39 was damaged in ITP patients and improved after high-dose dexamethasone therapy. In ITP, there was not only numerical decrease but also impaired enzymatic activity in CD39+ Treg cells. After high-dose dexamethasone treatment, these two defects could be reversed. Our results also suggested that ITP patients had reduced A2AR expression in both CD4+CD25+ Treg cells and CD4+CD25- Teff cells. CD4+CD25- Teff cells had increased A2AR expression after treatment.


Subject(s)
Apyrase/genetics , Dexamethasone/therapeutic use , Immunosuppressive Agents/therapeutic use , Purpura, Thrombocytopenic, Idiopathic/drug therapy , Receptor, Adenosine A2A/genetics , T-Lymphocytes, Regulatory/drug effects , Adenosine/immunology , Adenosine/metabolism , Adenosine Triphosphate/immunology , Adenosine Triphosphate/metabolism , Adult , Aged , Apyrase/immunology , Case-Control Studies , Female , Gene Expression , Humans , Immunophenotyping , Lymphocyte Count , Male , Middle Aged , Purpura, Thrombocytopenic, Idiopathic/enzymology , Purpura, Thrombocytopenic, Idiopathic/genetics , Purpura, Thrombocytopenic, Idiopathic/immunology , Receptor, Adenosine A2A/immunology , T-Lymphocytes, Cytotoxic/drug effects , T-Lymphocytes, Cytotoxic/enzymology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Regulatory/enzymology , T-Lymphocytes, Regulatory/immunology
9.
J Pharmacol Sci ; 139(3): 209-214, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30773300

ABSTRACT

The aim of this study was to investigate the contribution of gene polymorphisms, in combination with habitual caffeine consumption, to the effect of caffeine intake on hemodynamic and psychoactive parameters. A double-blind, prospective study was conducted with 201 healthy volunteers randomly allocated 2:1 to the caffeinated group (150 mL decaffeinated coffee with additional 200 mg caffeine) or decaffeinated group (150 mL decaffeinated coffee). We measured the changes in blood pressure (BP) and calculation speed upon coffee intake, stratifying with gene polymorphisms, e.g., those in adenosine A2A receptor (ADORA2A) and cytochrome P450 (CYP) 1A2, and daily caffeine consumption (≤90 mg/day and >90 mg/day). Overall, caffeine intake independently increased BP and calculation speed (p-values < 0.05), irrespective of the polymorphisms. In stratified analysis, a statistical significance within the caffeinated group was observed for the change in systolic BP in the stratum of CYP1A2 polymorphism with daily caffeine consumption ≤90 mg/day: change in systolic BP in the CYP1A2 rs762551 CC group (mean ± SD = 11.8 ± 5.9) was higher than that in the AA/CA group (4.1 ± 5.5). Gene polymorphisms may limitedly modify the effect of caffeine intake on hemodynamic parameters in combination with habitual caffeine consumption.


Subject(s)
Blood Pressure/drug effects , Caffeine/pharmacology , Cytochrome P-450 CYP1A2/genetics , Heart Rate/drug effects , Coffee , Double-Blind Method , Female , Humans , Male , Mathematics , Polymorphism, Genetic , Prospective Studies , Receptor, Adenosine A2A/genetics , Young Adult
10.
Neuropharmacology ; 144: 122-132, 2019 01.
Article in English | MEDLINE | ID: mdl-30336152

ABSTRACT

Insomnia is one of the most common sleep problems with an estimated prevalence of 10%-15% in the general population. Although adenosine A2A receptor (A2AR) agonists strongly induce sleep, their cardiovascular effects preclude their use in treating sleep disorders. Enhancing endogenous A2AR signaling, however, may be an alternative strategy for treating insomnia, because adenosine levels in the brain accumulate during wakefulness. In the present study, we found that 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid, denoted A2AR positive allosteric modulator (PAM)-1, enhanced adenosine signaling at the A2AR and induced slow wave sleep (SWS) without affecting body temperature in wild-type male mice after intraperitoneal administration, whereas the SWS-inducing effect of this benzoic acid derivative was abolished in A2AR KO mice. In contrast to the A2AR agonist CGS 21680, the A2AR PAM-1 did not affect blood pressure or heart rate. These findings indicate that enhancing A2AR signaling promotes SWS without cardiovascular effects. Therefore, small molecules that allosterically modulate A2ARs could help people with insomnia to fall asleep.


Subject(s)
Adenosine A2 Receptor Agonists/pharmacology , Hypnotics and Sedatives/pharmacology , Sleep, Slow-Wave/drug effects , Adenosine/analogs & derivatives , Adenosine/metabolism , Adenosine/pharmacology , Adenosine A2 Receptor Agonists/chemical synthesis , Allosteric Regulation , Animals , Blood Pressure/drug effects , Blood Pressure/physiology , Body Temperature/drug effects , CHO Cells , Cricetulus , Drug Evaluation, Preclinical , Heart Rate/drug effects , Heart Rate/physiology , Male , Mice, Inbred C57BL , Mice, Knockout , Phenethylamines/pharmacology , Random Allocation , Receptor, Adenosine A2A/genetics , Receptor, Adenosine A2A/metabolism , Signal Transduction/drug effects , Sleep, Slow-Wave/physiology , Wakefulness/drug effects , Wakefulness/physiology
11.
BMC Complement Altern Med ; 18(1): 330, 2018 Dec 12.
Article in English | MEDLINE | ID: mdl-30541517

ABSTRACT

BACKGROUND: Baicalin is a flavonoid compound that exerts specific pharmacological effect in attenuating the proliferation, migration, and apoptotic resistance of hypoxia-induced pulmonary artery smooth muscle cells (PASMCs). However, the underlying mechanism has not been fully elucidated yet. Although our previous studies had indicated that activation of A2aR attenuates CXCR expression, little is known about the relationship between A2aR and SDF-1/CXCR4 axis in hypoxic PASMCs. In this study, we aimed to investigate the effect of A2aR on the SDF-1/CXCR4 axis in hypoxic PASMCs, the mechanism underlying this effect, and whether baicalin exerts its protective functions though A2aR. METHODS: Rat PASMCs were cultured under normoxia/hypoxia and divided into nine groups: normoxia, hypoxia, hypoxia + AMD3100 (a CXCR4 antagonist), hypoxia + baicalin, hypoxia + negative virus, normoxia + A2aR knockdown, hypoxia + A2aR knockdown, hypoxia + CGS21680 (an A2aR agonist), and hypoxia + A2aR knockdown + baicalin. Lentiviral transfection methods were used to establish the A2aR knockdown model in PASMCs. Cells were incubated under hypoxic conditions for 24 h. Expression levels of A2aR, SDF-1, and CXCR4 were detected using RT-qPCR and western blot. The proliferation and migration rate were observed via CCK-8 and Transwell methods. Cell cycle distribution and cell apoptosis were measured by flow cytometry (FCM) and the In-Situ Cell Death Detection kit (Fluorescein). RESULTS: Under hypoxic conditions, levels of A2aR, SDF-1, and CXCR4 were significantly increased compared to those under normoxia. The trend of SDF-1 and CXCR4 being inhibited when A2aR is up-regulated was more obvious in the baicalin intervention group. Baicalin directly enhanced A2aR expression, and A2aR knockdown weakened the function of baicalin. SDF-1 and CXCR4 expression levels were increased in the hypoxia + A2aR knockdown group, as were the proliferation and migration rates of PASMCs, while the apoptotic rate was decreased. Baicalin and CGS21680 showed opposite effects. CONCLUSIONS: Our data indicate that baicalin efficiently attenuates hypoxia-induced PASMC proliferation, migration, and apoptotic resistance, as well as SDF-1 secretion, by up-regulating A2aR and down-regulating the SDF-1/CXCR4 axis.


Subject(s)
Apoptosis/drug effects , Cell Hypoxia , Chemokine CXCL12/metabolism , Flavonoids/pharmacology , Receptor, Adenosine A2A/metabolism , Receptors, CXCR4/metabolism , Animals , Cell Movement/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Chemokine CXCL12/analysis , Chemokine CXCL12/genetics , Male , Myocytes, Smooth Muscle , Pulmonary Artery/cytology , Rats , Rats, Sprague-Dawley , Receptor, Adenosine A2A/analysis , Receptor, Adenosine A2A/genetics , Receptors, CXCR4/analysis , Receptors, CXCR4/genetics , Up-Regulation/drug effects
12.
Nutrients ; 10(10)2018 Sep 21.
Article in English | MEDLINE | ID: mdl-30248915

ABSTRACT

Caffeine use is widespread among athletes following its removal from the World Anti-Doping Agency banned list, with approximately 75% of competitive athletes using caffeine. While literature supports that caffeine has a small positive ergogenic effect for most forms of sports and exercise, there exists a significant amount of inter-individual difference in the response to caffeine ingestion and the subsequent effect on exercise performance. In this narrative review, we discuss some of the potential mechanisms and focus on the role that genetics has in these differences. CYP1A2 and ADORA2A are two of the genes which are thought to have the largest impact on the ergogenicity of caffeine. CYP1A2 is responsible for the majority of the metabolism of caffeine, and ADORA2A has been linked to caffeine-induced anxiety. The effects of CYP1A2 and ADORA2A genes on responses to caffeine will be discussed in detail and an overview of the current literature will be presented. The role of these two genes may explain a large portion of the inter-individual variance reported by studies following caffeine ingestion. Elucidating the extent to which these genes moderate responses to caffeine during exercise will ensure caffeine supplementation programs can be tailored to individual athletes in order to maximize the potential ergogenic effect.


Subject(s)
Caffeine/pharmacology , Central Nervous System Stimulants/pharmacology , Cytochrome P-450 CYP1A2/genetics , Exercise/physiology , Performance-Enhancing Substances/pharmacology , Physical Endurance/genetics , Receptor, Adenosine A2A/genetics , Anxiety/genetics , Athletes/psychology , Athletic Performance/psychology , Cytochrome P-450 CYP1A2/metabolism , Dietary Supplements , Doping in Sports , Exercise/psychology , Humans , Individuality , Physical Endurance/drug effects , Precision Medicine , Receptor, Adenosine A2A/metabolism
13.
Nat Neurosci ; 21(1): 29-32, 2018 01.
Article in English | MEDLINE | ID: mdl-29180747

ABSTRACT

Excitation of accumbal D2 cells governs vital actions, including avoidance of learned risks, but the origins of this excitation and roles of D2 cells in innate risk-avoidance are unclear. Hypothalamic neurons producing orexins (also called hypocretins) enhance innate risk-avoidance via poorly understood neurocircuits. We describe a direct orexin→D2 excitatory circuit and show that D2 cell activity is necessary for orexin-dependent innate risk-avoidance in mice, thus revealing an unsuspected hypothalamus-accumbens interplay in action selection.


Subject(s)
Avoidance Learning/physiology , Instinct , Neurons/physiology , Orexins/metabolism , Signal Transduction/physiology , 2-Amino-5-phosphonovalerate/pharmacology , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Animals , Channelrhodopsins/genetics , Channelrhodopsins/metabolism , Excitatory Amino Acid Antagonists/pharmacology , Hypothalamic Hormones/genetics , Hypothalamic Hormones/metabolism , Hypothalamus/cytology , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Melanins/genetics , Melanins/metabolism , Mice , Mice, Transgenic , Nerve Net/drug effects , Nerve Net/physiology , Neurons/drug effects , Neuropeptide Y/genetics , Neuropeptide Y/metabolism , Orexins/genetics , Pituitary Hormones/genetics , Pituitary Hormones/metabolism , Receptor, Adenosine A2A/genetics , Receptor, Adenosine A2A/metabolism , Receptors, Dopamine D1/genetics
14.
J Biomed Sci ; 24(1): 52, 2017 Aug 03.
Article in English | MEDLINE | ID: mdl-28774332

ABSTRACT

BACKGROUND: Baicalin, an important flavonoid in Scutellaria baicalensis Georgi extracts, exerts a variety of pharmacological effects. In this study, we explored the effects of baicalin on chronic hypoxia-induced pulmonary arterial hypertension (PAH) and investigated the mechanism underlying these effects. Moreover, we examined whether the inflammatory response was mediated by the A2A receptor (A2AR) and stromal cell-derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4)-induced phosphatidyl inositol-3-kinase (PI3K) signaling in vivo. METHODS: We established a hypoxia-induced pulmonary hypertension (HPH) mouse model by subjecting wild-type (WT) and A2AR knockout (A2AR-/-) animals to chronic hypoxia, and we examined the effects of a 4-week treatment with baicalin or the A2AR agonist CGS21680 in these animals. Invasive hemodynamic parameters, the right ventricular hypertrophy index, pulmonary congestion, the pulmonary arterial remodeling index, blood gas parameters, A2AR expression, and the expression of SDF-1/CXCR4/PI3K/protein kinase B (PKB; AKT) signaling components were measured. RESULTS: Compared with WT mice, A2AR-/- mice exhibited increased right ventricular systolic pressure (RVSP), right ventricle-to-left ventricle plus septum [RV/(LV + S)] ratio, RV weight-to-body weight (RV/BW) ratio, and lung wet weight-to-body weight (Lung/BW) ratio in the absence of an altered mean carotid arterial pressure (mCAP). These changes were accompanied by increases in pulmonary artery wall area and thickness and reductions in arterial oxygen pressure (PaO2) and hydrogen ion concentration (pH). In the HPH model, A2AR-/- mice displayed increased CXCR4, SDF-1, phospho-PI3K, and phospho-AKT expression compared with WT mice. Treating WT and A2AR-/- HPH mice with baicalin or CGS21680 attenuated the hypoxia-induced increases in RVSP, RV/(LV + S) and Lung/BW, as well as pulmonary arterial remodeling. Additionally, baicalin or CGS21680 alone could reverse the hypoxia-induced increases in CXCR4, SDF-1, phospho-PI3K, and phospho-AKT expression. Moreover, baicalin improved the hypoxemia induced by 4 weeks of hypoxia. Finally, we found that A2AR levels in WT lung tissue were enhanced by hypoxia and that baicalin up-regulated A2AR expression in WT hypoxic mice. CONCLUSIONS: Baicalin exerts protective effects against clinical HPH, which are partly mediated through enhanced A2AR activity and down-regulated SDF-1/CXCR4-induced PI3K/AKT signaling. Therefore, the A2AR may be a promising target for baicalin in treating HPH.


Subject(s)
Adenosine A2 Receptor Agonists/pharmacology , Adenosine/analogs & derivatives , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Flavonoids/pharmacology , Hypertension, Pulmonary/physiopathology , Phenethylamines/pharmacology , Signal Transduction/drug effects , Adenosine/pharmacology , Adenosine/therapeutic use , Adenosine A2 Receptor Agonists/therapeutic use , Animals , Antihypertensive Agents/pharmacology , Antihypertensive Agents/therapeutic use , Hypertension, Pulmonary/drug therapy , Male , Mice , Mice, Inbred BALB C , Phenethylamines/therapeutic use , Random Allocation , Receptor, Adenosine A2A/genetics
15.
Microb Cell Fact ; 16(1): 41, 2017 Mar 09.
Article in English | MEDLINE | ID: mdl-28279185

ABSTRACT

BACKGROUND: We previously selected four strains of Saccharomyces cerevisiae for their ability to produce the aquaporin Fps1 in sufficient yield for further study. Yields from the yeast strains spt3Δ, srb5Δ, gcn5Δ and yTHCBMS1 (supplemented with 0.5 µg/mL doxycycline) that had been transformed with an expression plasmid containing 249 base pairs of 5' untranslated region (UTR) in addition to the primary FPS1 open reading frame (ORF) were 10-80 times higher than yields from wild-type cells expressing the same plasmid. One of the strains increased recombinant yields of the G protein-coupled receptor adenosine receptor 2a (A2aR) and soluble green fluorescent protein (GFP). The specific molecular mechanisms underpinning a high-yielding Fps1 phenotype remained incompletely described. RESULTS: Polysome profiling experiments were used to analyze the translational state of spt3Δ, srb5Δ, gcn5Δ and yTHCBMS1 (supplemented with 0.5 µg/mL doxycycline); all but gcn5Δ were found to exhibit a clear block in translation initiation. Four additional strains with known initiation blocks (rpl31aΔ, rpl22aΔ, ssf1Δ and nop1Δ) also improved the yield of recombinant Fps1 compared to wild-type. Expression of the eukaryotic transcriptional activator GCN4 was increased in spt3Δ, srb5Δ, gcn5Δ and yTHCBMS1 (supplemented with 0.5 µg/mL doxycycline); these four strains also exhibited constitutive phosphorylation of the eukaryotic initiation factor, eIF2α. Both responses are indicative of a constitutively-stressed phenotype. Investigation of the 5'UTR of FPS1 in the expression construct revealed two untranslated ORFs (uORF1 and uORF2) upstream of the primary ORF. Deletion of either uORF1 or uORF1 and uORF2 further improved recombinant yields in our four strains; the highest yields of the uORF deletions were obtained from wild-type cells. Frame-shifting the stop codon of the native uORF (uORF2) so that it extended into the FPS1 ORF did not substantially alter Fps1 yields in spt3Δ or wild-type cells, suggesting that high-yielding strains are able to bypass 5'uORFs in the FPS1 gene via leaky scanning, which is a known stress-response mechanism. Yields of recombinant A2aR, GFP and horseradish peroxidase could be improved in one or more of the yeast strains suggesting that a stressed phenotype may also be important in high-yielding cell factories. CONCLUSIONS: Regulation of Fps1 levels in yeast by translational control may be functionally important; the presence of a native uORF (uORF2) may be required to maintain low levels of Fps1 under normal conditions, but higher levels as part of a stress response. Constitutively-stressed yeast strains may be useful high-yielding microbial cell factories for recombinant protein production.


Subject(s)
Aquaporin 1/biosynthesis , Aquaporin 1/genetics , Gene Expression Regulation, Fungal , Peptide Chain Initiation, Translational/genetics , Saccharomyces cerevisiae/genetics , 5' Untranslated Regions , Codon, Terminator , Doxycycline/pharmacology , Genes, Fungal , Green Fluorescent Proteins/genetics , Open Reading Frames , Plasmids/genetics , Polyribosomes , Receptor, Adenosine A2A/biosynthesis , Receptor, Adenosine A2A/genetics , Recombinant Proteins/biosynthesis , Saccharomyces cerevisiae/drug effects , Saccharomyces cerevisiae Proteins/genetics
16.
Neuroepidemiology ; 47(3-4): 192-200, 2016.
Article in English | MEDLINE | ID: mdl-28135712

ABSTRACT

BACKGROUND AND PURPOSE: Drinking caffeinated coffee has been reported to provide protection against Parkinson's disease (PD). Caffeine is an adenosine A2A receptor (encoded by the gene ADORA2A) antagonist that increases dopaminergic neurotransmission and Cytochrome P450 1A2 (gene: CYP1A2) metabolizes caffeine; thus, gene polymorphisms in ADORA2A and CYP1A2 may influence the effect coffee consumption has on PD risk. METHODS: In a population-based case-control study (PASIDA) in Denmark (1,556 PD patients and 1,606 birth year- and gender-matched controls), we assessed interactions between lifetime coffee consumption and 3 polymorphisms in ADORA2A and CYP1A2 for all subjects, and incident and prevalent PD cases separately using logistic regression models. We also conducted a meta-analysis combining our results with those from previous studies. RESULTS: We estimated statistically significant interactions for ADORA2A rs5760423 and heavy vs. light coffee consumption in incident (OR interaction = 0.66 [95% CI 0.46-0.94], p = 0.02) but not prevalent PD. We did not observe interactions for CYP1A2 rs762551 and rs2472304 in incident or prevalent PD. In meta-analyses, PD associations with daily coffee consumption were strongest among carriers of variant alleles in both ADORA2A and CYP1A2. CONCLUSION: We corroborated results from a previous report that described interactions between ADORA2A and CYP1A2 polymorphisms and coffee consumption. Our results also suggest that survivor bias may affect results of studies that enroll prevalent PD cases.


Subject(s)
Coffee , Cytochrome P-450 CYP1A2/genetics , Gene-Environment Interaction , Parkinson Disease/epidemiology , Parkinson Disease/genetics , Receptor, Adenosine A2A/genetics , Aged , Denmark , Female , Humans , Male , Middle Aged , Polymorphism, Single Nucleotide , Risk Factors
17.
J Med Chem ; 58(7): 3253-67, 2015 Apr 09.
Article in English | MEDLINE | ID: mdl-25780876

ABSTRACT

Stimulation of A2A adenosine receptors (AR) promotes anti-inflammatory responses in animal models of allergic rhinitis, asthma, chronic obstructive pulmonary disease, and rheumatic diseases. Herein we describe the results of a research program aimed at identifying potent and selective agonists of the A2AAR as potential anti-inflammatory agents. The recent crystallographic analysis of A2AAR agonists and antagonists in complex with the receptor provided key information on the structural determinants leading to receptor activation or blocking. In light of this, we designed a new series of 2-((4-aryl(alkyl)piperazin-1-yl)alkylamino)-5'-N-ethylcarboxamidoadenosines with high A2AAR affinity, activation potency and selectivity obtained by merging distinctive structural elements of known agonists and antagonists of the investigated target. Docking-based SAR optimization allowed us to identify compound 42 as one of the most potent and selective A2A agonist discovered so far (Ki hA2AAR = 4.8 nM, EC50 hA2AAR = 4.9 nM, Ki hA1AR > 10 000 nM, Ki hA3AR = 1487 nM, EC50 hA2BAR > 10 000 nM).


Subject(s)
Adenosine A2 Receptor Agonists/chemistry , Adenosine A2 Receptor Agonists/pharmacology , Receptor, Adenosine A2A/chemistry , Adenosine A2 Receptor Agonists/chemical synthesis , Adenosine A2 Receptor Agonists/metabolism , Adenosine-5'-(N-ethylcarboxamide)/chemistry , Animals , CHO Cells/drug effects , Chemistry Techniques, Synthetic , Cricetulus , Crystallography, X-Ray , Drug Design , Drug Evaluation, Preclinical/methods , Humans , Molecular Docking Simulation , Receptor, Adenosine A2A/genetics , Receptor, Adenosine A2A/metabolism , Structure-Activity Relationship
18.
J Chem Inf Model ; 55(3): 550-63, 2015 Mar 23.
Article in English | MEDLINE | ID: mdl-25625646

ABSTRACT

Crystal structures of G protein-coupled receptors (GPCRs) have recently revealed the molecular basis of ligand binding and activation, which has provided exciting opportunities for structure-based drug design. The A2A adenosine receptor (A2AAR) is a promising therapeutic target for cardiovascular diseases, but progress in this area is limited by the lack of novel agonist scaffolds. We carried out docking screens of 6.7 million commercially available molecules against active-like conformations of the A2AAR to investigate whether these structures could guide the discovery of agonists. Nine out of the 20 predicted agonists were confirmed to be A2AAR ligands, but none of these activated the ARs. The difficulties in discovering AR agonists using structure-based methods originated from limited atomic-level understanding of the activation mechanism and a chemical bias toward antagonists in the screened library. In particular, the composition of the screened library was found to strongly reduce the likelihood of identifying AR agonists, which reflected the high ligand complexity required for receptor activation. Extension of this analysis to other pharmaceutically relevant GPCRs suggested that library screening may not be suitable for targets requiring a complex receptor-ligand interaction network. Our results provide specific directions for the future development of novel A2AAR agonists and general strategies for structure-based drug discovery.


Subject(s)
Adenosine A2 Receptor Agonists/chemistry , Drug Discovery/methods , Molecular Docking Simulation , Structure-Activity Relationship , Adenosine A2 Receptor Agonists/metabolism , Adenosine A2 Receptor Agonists/pharmacology , Adenosine A2 Receptor Antagonists/chemistry , Adenosine A2 Receptor Antagonists/pharmacology , Animals , CHO Cells/drug effects , Cricetulus , Drug Design , Drug Evaluation, Preclinical/methods , Humans , Ligands , Prospective Studies , Protein Conformation , Receptor, Adenosine A2A/chemistry , Receptor, Adenosine A2A/genetics , Receptor, Adenosine A2A/metabolism , Receptors, G-Protein-Coupled/chemistry , Receptors, G-Protein-Coupled/metabolism
19.
Neurobiol Dis ; 59: 141-50, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23851307

ABSTRACT

Inflammation in the central nervous system (CNS) is a complex process that involves a multitude of molecules and effectors, and it requires the transmigration of blood leukocytes across the blood-brain barrier (BBB) and the activation of resident immune cells. Cannabidiol (CBD), a non-psychotropic cannabinoid constituent of Cannabis sativa, has potent anti-inflammatory and immunosuppressive properties. Yet, how this compound modifies the deleterious effects of inflammation in TMEV-induced demyelinating disease (TMEV-IDD) remains unknown. Using this viral model of multiple sclerosis (MS), we demonstrate that CBD decreases the transmigration of blood leukocytes by downregulating the expression of vascular cell adhesion molecule-1 (VCAM-1), chemokines (CCL2 and CCL5) and the proinflammatory cytokine IL-1ß, as well as by attenuating the activation of microglia. Moreover, CBD administration at the time of viral infection exerts long-lasting effects, ameliorating motor deficits in the chronic phase of the disease in conjunction with reduced microglial activation and pro-inflammatory cytokine production. Adenosine A2A receptors participate in some of the anti-inflammatory effects of CBD, as the A2A antagonist ZM241385 partially blocks the protective effects of CBD in the initial stages of inflammation. Together, our findings highlight the anti-inflammatory effects of CBD in this viral model of MS and demonstrate the significant therapeutic potential of this compound for the treatment of pathologies with an inflammatory component.


Subject(s)
Cannabidiol/therapeutic use , Inflammation/drug therapy , Inflammation/etiology , Multiple Sclerosis , Receptor, Adenosine A2A/metabolism , Animals , Brain/cytology , Cardiovirus Infections/complications , Cell Adhesion/drug effects , Cell Adhesion/physiology , Cells, Cultured , Chemokine CCL2/genetics , Chemokine CCL2/metabolism , Chemokine CCL5/genetics , Chemokine CCL5/metabolism , Disease Models, Animal , Endothelial Cells/drug effects , Endothelial Cells/virology , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Mice , Motor Activity/drug effects , Motor Activity/physiology , Multiple Sclerosis/complications , Multiple Sclerosis/etiology , Multiple Sclerosis/virology , Receptor, Adenosine A2A/genetics , Triazines/pharmacology , Triazoles/pharmacology , Vascular Cell Adhesion Molecule-1/genetics , Vascular Cell Adhesion Molecule-1/metabolism
20.
PLoS One ; 8(3): e59257, 2013.
Article in English | MEDLINE | ID: mdl-23555007

ABSTRACT

Sinomenine (SIN) is a bioactive alkaloid extracted from the Chinese medicinal plant Sinomenium acutum, which is widely used in the clinical treatment of rheumatoid arthritis (RA). However, its role in acute lung injury (ALI) is unclear. In this study, we investigate the role of SIN in lipopolysaccharide (LPS)-induced ALI in mice. After ALI, lung water content and histological signs of pulmonary injury were attenuated, whereas the PaO2/FIO2 (P/F) ratios were elevated significantly in the mice pretreated with SIN. Additionally, SIN markedly inhibited inflammatory cytokine TNF-α and IL-1ß expression levels as well as neutrophil infiltration in the lung tissues of the mice. Microarray analysis and real-time PCR showed that SIN treatment upregulated adenosine A(2A) receptor (A(2A)R) expression, and the protective effect of SIN was abolished in A(2A)R knockout mice. Further investigation in isolated mouse neutrophils confirmed the upregulation of A(2A)R by SIN and showed that A(2A)R-cAMP-PKA signaling was involved in the anti-inflammatory effect of SIN. Taken together, these findings demonstrate an A(2A)R-associated anti-inflammatory effect and the protective role of SIN in ALI, which suggests a potential novel approach to treat ALI.


Subject(s)
Acute Lung Injury/prevention & control , Gene Expression Regulation/drug effects , Morphinans/pharmacology , Receptor, Adenosine A2A/genetics , Signal Transduction/drug effects , Acute Lung Injury/chemically induced , Acute Lung Injury/genetics , Acute Lung Injury/pathology , Animals , Cells, Cultured , Cyclic AMP/metabolism , Cyclic AMP-Dependent Protein Kinases/genetics , Cyclic AMP-Dependent Protein Kinases/metabolism , Gene Expression Profiling , Interleukin-1beta/antagonists & inhibitors , Interleukin-1beta/biosynthesis , Lipopolysaccharides , Mice , Mice, Knockout , Neutrophils/drug effects , Neutrophils/metabolism , Receptor, Adenosine A2A/deficiency , Sinomenium/chemistry , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL